RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Cosmo Pharmaceuticals - Stock

Cosmo Pharmaceuticals P/E 2024

Cosmo Pharmaceuticals P/E

9.8

Ticker

COPN.SW

ISIN

NL0011832936

WKN

A2AJ68

As of Jun 20, 2024, Cosmo Pharmaceuticals's P/E ratio was 9.8, a -98.58% change from the 688.78 P/E ratio recorded in the previous year.

The Cosmo Pharmaceuticals P/E history

Cosmo Pharmaceuticals Aktienanalyse

What does Cosmo Pharmaceuticals do?

Cosmo Pharmaceuticals NV is an international pharmaceutical company based in Dublin, Ireland. The company focuses on developing innovative drugs for various diseases, including gastroenterology, oncology, and infectious diseases. The history of Cosmo Pharmaceuticals dates back to 1997 when it was founded by Dr. Mauro Ajani in Italy. Since then, the company has undergone impressive development and is now listed on the SIX Swiss Exchange. In 2020, the company moved from Italy to Ireland to strengthen its international presence. Cosmo Pharmaceuticals' business model is based on creating patented innovations and technologies in drug development. The company works closely with other companies and research institutions to introduce a wide range of products that benefit both patients and healthcare providers. The main source of income for Cosmo Pharmaceuticals is the licenses they grant for their products, as well as the manufacturing and sale of their own products. Cosmo Pharmaceuticals operates three main business areas: Human, Veterinary, and Proprietary. The Human division specializes in the development of drugs for humans. The company's products are available worldwide, including in the United States, Europe, Japan, and China. In the field of gastroenterology, Cosmo Pharmaceuticals is one of the leading companies on the market and has developed several products to treat gastrointestinal problems and other gastrointestinal diseases. The Veterinary division of Cosmo Pharmaceuticals specializes in the development of animal medicines. The company works with veterinarians and pet owners to bring products to market that help animals stay healthy or recover. Cosmo Pharmaceuticals offers several products tailored to the specific needs of animals, including Ballistol Animal, used for skin and fur care, and Otilonium Bromide, used for digestive disorders in horses. The Proprietary division is the third major business area of Cosmo Pharmaceuticals. This is a segment that manufactures its own products and sells them directly to patients or institutions. The company's products include Eleview, used in endoscopy to improve visibility of the gastrointestinal mucosa. Cosmo Pharmaceuticals is an innovative company focused on the development of drugs that can help improve patients' lives. The company collaborates closely with other companies and research institutions to leverage the latest technologies and developments in the industry. With its broad portfolio of products in the field of gastroenterology, oncology, and infectious diseases, the company has a strong presence in the industry and actively advocates for more people to have access to the best medical treatments. Cosmo Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Cosmo Pharmaceuticals's P/E Ratio

The Price to Earnings (P/E) Ratio of Cosmo Pharmaceuticals is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Cosmo Pharmaceuticals's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Cosmo Pharmaceuticals is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Cosmo Pharmaceuticals’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Cosmo Pharmaceuticals Stock

What is the price-to-earnings ratio of Cosmo Pharmaceuticals?

The price-earnings ratio of Cosmo Pharmaceuticals is currently 9.8.

How has the price-earnings ratio of Cosmo Pharmaceuticals changed compared to last year?

The price-to-earnings ratio of Cosmo Pharmaceuticals has increased by -98.58% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Cosmo Pharmaceuticals high compared to other companies?

Yes, the price-to-earnings ratio of Cosmo Pharmaceuticals is high compared to other companies.

How does an increase in the price-earnings ratio of Cosmo Pharmaceuticals affect the company?

An increase in the price-earnings ratio of Cosmo Pharmaceuticals would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Cosmo Pharmaceuticals affect the company?

A decrease in the price-earnings ratio of Cosmo Pharmaceuticals would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Cosmo Pharmaceuticals?

Some factors that influence the price-earnings ratio of Cosmo Pharmaceuticals are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Cosmo Pharmaceuticals pay?

Over the past 12 months, Cosmo Pharmaceuticals paid a dividend of 1.05 EUR . This corresponds to a dividend yield of about 1.42 %. For the coming 12 months, Cosmo Pharmaceuticals is expected to pay a dividend of 1.05 EUR.

What is the dividend yield of Cosmo Pharmaceuticals?

The current dividend yield of Cosmo Pharmaceuticals is 1.42 %.

When does Cosmo Pharmaceuticals pay dividends?

Cosmo Pharmaceuticals pays a quarterly dividend. This is distributed in the months of June, July, June, June.

How secure is the dividend of Cosmo Pharmaceuticals?

Cosmo Pharmaceuticals paid dividends every year for the past 8 years.

What is the dividend of Cosmo Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 1.05 EUR are expected. This corresponds to a dividend yield of 1.42 %.

In which sector is Cosmo Pharmaceuticals located?

Cosmo Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cosmo Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cosmo Pharmaceuticals from 5/30/2024 amounting to 2.17 EUR, you needed to have the stock in your portfolio before the ex-date on 5/28/2024.

When did Cosmo Pharmaceuticals pay the last dividend?

The last dividend was paid out on 5/30/2024.

What was the dividend of Cosmo Pharmaceuticals in the year 2023?

In the year 2023, Cosmo Pharmaceuticals distributed 0.95 EUR as dividends.

In which currency does Cosmo Pharmaceuticals pay out the dividend?

The dividends of Cosmo Pharmaceuticals are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Cosmo Pharmaceuticals

Our stock analysis for Cosmo Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cosmo Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.